Analgesics
Antiandrogens
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lactoferrin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Quercetin
Remdesivir
Vitamins

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 15% Improvement Relative Risk HCQ for COVID-19  Shoaibi et al.  LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 29,451 patients in the USA Lower mortality with HCQ (p=0.001) c19hcq.org Shoaibi et al., medRxiv, September 2020 Favors HCQ Favors control

Comparative Effectiveness of Famotidine in Hospitalized COVID-19 Patients

Shoaibi et al., medRxiv, doi:10.1101/2020.09.23.20199463
Sep 2020  
  Twitter
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Retrospective database analysis focused on Famotidine but also showing results for HCQ users, with unadjusted mortality RR 0.85, p<0.001 (13.6% vs. 16.1%). This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details.
risk of death, 15.4% lower, RR 0.85, p < 0.001, treatment 686 of 5,047 (13.6%), control 3,923 of 24,404 (16.1%), NNT 40.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Shoaibi et al., 24 Sep 2020, retrospective, database analysis, USA, preprint, 5 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Comparative Effectiveness of Famotidine in Hospitalized COVID-19 Patients
PhD Azza Shoaibi, PharmD Stephen Fortin, MS Rachel Weinstein, Jesse A Berlin, PhD Patrick Ryan
doi:10.1101/2020.09.23.20199463
All authors contributed to the conceptualization and design of the study. SF authored the protocol of the study design, AS implemented the statistical analysis, RW, PBR and JB reviewed and approved the study diagnostics and results. AS drafted the manuscript and all coauthors reviewed and contributed to the manuscript writing. .
References
Austin, Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research, Communications in statistics-simulation and computation
Bourinbaiar, Fruhstorfer, The effect of histamine type 2 receptor antagonists on human immunodeficiency virus (HIV) replication: identification of a new class of antiviral agents, Life sciences
Cheung, Hung, Leung, Association between famotidine use and COVID-19 severity in Hong Kong: a territory-wide study, Gastroenterology
Freedberg, Conigliaro, Wang, Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: A propensity score matched retrospective cohort study, Gastroenterology
Howden, Tytgat, The tolerability and safety profile of famotidine, Clinical therapeutics
Janowitz, Gablenz, Pattinson, Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series, Gut
Kritas, Ronconi, Caraffa, Mast cells contribute to coronavirus-induced inflammation: new anti-inflammatory strategy, J Biol Regul Homeost Agents
Malone, Tisdall, Smith, COVID-19: Famotidine, histamine, mast cells, and mechanisms
Mather, Seip, Mckay, Impact of Famotidine Use on Clinical Outcomes of Hospitalized Patients With COVID-19, Official journal of the American College of Gastroenterology| ACG
Suchard, Schuemie, Krumholz, Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis, The Lancet
Walker, Patrick, Lauer, A tool for assessing the feasibility of comparative effectiveness research, Comp Eff Res
Wu, Liu, Yang, Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods, Acta Pharmaceutica Sinica B
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit